We focussed on the IDH1 mutation since we had previously developed an inducible AML cell line that expresses mutant IDH1 (ref. 27), providing us with an appropriate experimental system to test MiSL candidates. This evidence concerns the gene IDH1 and acute myeloid leukemia.